Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Prototype Test Developed for Ocular Trachoma

By LabMedica International staff writers
Posted on 15 Aug 2011
An evaluation has been made of a prototype point-of-care (POC) test, developed for field diagnosis of ocular Chlamydia trachomatis, in low prevalence settings. More...


The clinical signs of active trachoma are often present in the absence of ocular C. trachomatis infection in low prevalence and mass treated settings and treatment decisions are currently based on the prevalence of clinical signs.

A simple point-of-care (POC) test has been compared in laboratory testing for C. trachomatis infection to a polymerase chain reaction (PCR) which is highly sensitive but expensive and requires well-trained staff. Scientists from the London School of Hygiene and Tropical Medicine, (London, UK), working with others in the Gambia and Sengal screened children under the age of 10 for signs of trachoma. Two ocular swabs were taken from the right eye. The first swab was tested by the POC test in the field. This assay detects the chlamydial lipopolysaccharide (LPS), using lateral flow technology and this assay was designed specifically for use in resource-limited settings, and therefore has no electricity, water, or laboratory equipment requirements. The second swab was tested for the presence of C. trachomatis by Amplicor PCR.

A total of 3,734 children were screened, 950 in the first and 1,171 in the second Gambian study, and 1,613 in Senegal. The sensitivity of the prototype POC test (Diagnostics Development Unit, University of Cambridge, UK), ranged between 33.3% and 67.9%, the specificity was between 92.4% and 99.0%. The positive predictive value ranged between 4.3% and 21.0%, and the negative predictive value was between 98.0% and 99.8%. The rate of false-positives increased markedly at temperatures above 31.4 °C and relative humidities below 11.4%.

Although the POC test is a qualitative assay, the signal strength was scored on a scale from a weak 0.5 to a strong 5.0 in the field. There was a significant association between increased organism load and increased POC test signal strength. The Amplicor Chlamydia trachomatis PCR assay is a product of Roche Diagnostics (Burgess Hill, UK).

The authors concluded that the in its present format, this prototype POC test is not suitable for field diagnosis of ocular C. trachomatis as its specificity decreases in hot and dry conditions. In the absence of a suitable test for infection, trachoma diagnosis remains dependent on clinical signs and this will likely result in the unnecessary distribution of mass antibiotic treatment. The study was published on in the online journal Public Library of Science Neglected Tropical Diseases.

Related Links:
London School of Hygiene and Tropical Medicine
University of Cambridge
Roche diagnostics




Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.